EULAR 2026: Enhancing Rheumatology Patient Care and Experience

The European Alliance of Associations for Rheumatology (EULAR) Congress 2026 is currently underway in London, UK, from June 3-6, 2026, bringing together a vast community of clinicians, researchers, and patient advocates to share groundbreaking research and clinical insights in rheumatology. A central theme resonating throughout the congress is the imperative of 'Improving the Patient Experience in Rheumatology.' The discussions and presentations emphasize a holistic approach to patient care, moving beyond mere disease management to address the multifaceted impact of rheumatic and musculoskeletal diseases (RMDs) on patients' daily lives and their overall well-being. Strategies presented at EULAR 2026 aim to enhance the quality of life for individuals living with RMDs, focusing on critical areas such as fatigue management, the lived experiences of caregivers, the cost-effectiveness of patient education, and ensuring equitable access to rheumatology care. RMDs are known to profoundly affect daily life, limiting both work ability and participation in everyday activities, making these areas of focus particularly pertinent. One significant aspect highlighted is the pervasive issue of fatigue among patients with inflammatory arthritis. A feasibility study on the COMbined Fatigue Intervention (COMFI), presented by Astrid Damgaard at EULAR 2026, explored integrating tailored physical activity and cognitive behavioural approaches. Conducted with 29 patients in Denmark and Sweden, the study demonstrated that COMFI could be successfully delivered in both countries, with results indicating a tendency towards reduced fatigue after a six-month follow-up period. These findings are crucial as they suggest a viable, integrated approach to managing a common and burdensome symptom that significantly impacts patient experience. The congress also sheds light on the often-overlooked experiences of caregivers. Rikke Helene Moe, Vice-President of Health Professionals in Rheumatology, EULAR, emphasized the need to better include patient families in research and management strategies, acknowledging that the disease and its management significantly affect the entire family unit. An Italian phenomenological study presented at EULAR, which examined the lived experiences of 25 family members and primary informal caregivers, underscored the sustained support required from caregivers for patients' daily functioning. This focus recognizes the broader ecosystem of care surrounding RMD patients and the need for support systems that extend beyond the individual patient. Furthermore, the congress addresses the economic and practical dimensions of patient care, including the cost-effectiveness of patient education and improving access to rheumatology services. These discussions are vital for developing sustainable healthcare models that not only provide effective treatment but also empower patients through knowledge and ensure timely and appropriate care, especially in regions with varying healthcare infrastructures like India. Beyond patient experience, EULAR 2026 also serves as a platform for unveiling cutting-edge scientific advancements and new therapeutic options. Novartis, for instance, presented new data from 31 abstracts across its immunology portfolio, including the largest-ever global Phase III trial for Cosentyx® (secukinumab) in polymyalgia rheumatica (REPLENISH trial). Results from the REPLENISH trial demonstrated superior sustained remission in secukinumab-treated patients compared to placebo at week 52. Other presentations included interim results for ianalumab in Sjögren's disease and Phase II data in systemic lupus erythematosus, as well as advancements in CAR-T cell therapy for conditions like rheumatoid arthritis. These developments signify the ongoing quest for more effective treatments, which inherently contribute to an improved patient experience by offering better disease control and potentially enhanced quality of life. Sessions at EULAR 2026 also include innovative initiatives like 'The RheumaVision research knowledge transfer contest,' and discussions on 'Visual Abstracts and Science Communication in Rheumatology using AI,' indicating a commitment to advancing research methodologies and communication within the field. The presence of over 14,000 attendees, including clinicians, patients, and health professionals, underscores the broad interest and collaborative spirit driving advancements in rheumatology. While EULAR is a European organization, the scientific discoveries and discussions have global implications, offering valuable insights and potential future treatments for patients in India and worldwide facing similar challenges with RMDs. The emphasis on patient-reported outcomes (PROs) and patient-centered care models continues to gain traction, influencing how research is conducted and how treatments are delivered. The congress reinforces the understanding that effective rheumatology care must consider not just clinical efficacy but also the daily realities, preferences, and overall experience of the patient. The insights shared at EULAR 2026 are expected to shape future research agendas, clinical guidelines, and healthcare policies, ultimately fostering a more compassionate and effective approach to rheumatological care globally.

Frequently Asked Questions

Read Full Story on Quick Digest